期刊
CARCINOGENESIS
卷 30, 期 10, 页码 1696-1701出版社
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgp187
关键词
-
类别
资金
- Breakthrough Breast Cancer Research
- Tertiary Education Commission of New Zealand
Endocrine therapies, which inhibit estrogen receptor (ER)alpha signaling, are the most common and effective treatment for ER alpha-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The cyclin-dependent kinase family member CRK7 (aka CRKRS) was identified from an RNA interference screen for modifiers of tamoxifen sensitivity. Here, we demonstrate that silencing of CRK7 not only causes resistance to tamoxifen but also leads to resistance to additional endocrine therapies including ICI 182780 and estrogen deprivation, a model of aromatase inhibition. We show that CRK7 silencing activates the mitogen-activated protein kinase (MAPK)-signaling pathway, which causes a loss of ER dependence, resulting in endocrine therapy resistance. This study identifies a novel role for CRK7 in MAPK regulation and resistance to estrogen signaling inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据